# Is Scribe Therapeutics' Nasdaq IPO the Gene Editing Market's Comeback Signal?

Scribe Therapeutics has filed with the SEC to go public on the Nasdaq under ticker "SCTX" — the first gene editing company to attempt an IPO since Metagenomi raised nearly $94 million in 2024. The California biotech, which has banked $120 million in venture funding and secured pharma collaborations with Biogen, Sanofi, and Eli Lilly subsidiary Prevail Medicines, entered the clinic last month with its lead asset STX-1150, a single-dose epigenetic silencing treatment targeting PCSK9 for high cholesterol. If the offering prices, Scribe would become the 14th venture-backed biotech to go public in 2026 — a year already marked by two of the largest biotech IPOs on record. The deal would also be the first public market test of non-permanent [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9)-adjacent epigenomic editing as a standalone investment thesis, not just a platform licensing story.

The core question investors will ask: can a company with one Phase 1 asset, no revenue from product sales, and a differentiated but unproven epigenetic silencing mechanism sustain a public market valuation in a sector that has punished cell and gene therapy companies for five consecutive years since the 2021 peak?

---

## What Scribe Actually Does — and Why It's Different from Standard CRISPR

Scribe's technology does not permanently alter DNA sequences. Instead, STX-1150 uses epigenetic silencing to switch off the PCSK9 gene — the same target as established cholesterol drugs Repatha and Praluent — without making a heritable cut in the genome. The company's pitch is that a single administered dose could outperform both daily statin pills and quarterly injectable PCSK9 inhibitors currently on the market.

This is a meaningful clinical and commercial distinction, not merely a marketing angle. Permanent DNA editing carries regulatory scrutiny around off-target edits and long-term safety monitoring. Epigenetic silencing, if durable enough, could offer a middle path: long-lasting gene suppression without the off-target threshold concerns that shadow nuclease-based editing. The durability question — how long PCSK9 silencing persists after a single dose, and whether it requires re-dosing — will be the defining data point from the Phase 1 trial. The source material does not disclose half-life estimates or preclinical silencing duration data, so investors are pricing this on mechanism and management credibility, not efficacy readouts.

CEO Benjamin Oakes trained under Nobel laureate Jennifer Doudna, who co-founded the company. That lineage matters for scientific credibility but does not substitute for clinical data.

---

## The Pharma Partnership Stack: Validation or Revenue Bridge?

Scribe's collaboration portfolio is the strongest near-term argument for the IPO. Three separate deals with large-cap pharma cover distinct therapeutic areas:

- **Biogen**: Collaboration targeting ALS, announced shortly after Scribe's 2020 launch and subsequently expanded to a second, unnamed gene therapy target.
- **Sanofi**: An initial $25 million upfront payment for access to Scribe's platform to develop natural killer cell-based cancer treatments. Sanofi expanded the partnership in 2023 with an additional $40 million upfront focused on in vivo gene therapies.
- **Eli Lilly (Prevail Medicines)**: A neurological conditions deal worth up to $1.5 billion in total milestones, of which two undisclosed milestone payments have already been triggered.

The Lilly deal's $1.5 billion headline is the number bankers will feature prominently in the roadshow. But milestone-heavy deals are structured precisely because most milestones are never paid — that figure represents a theoretical ceiling across years of development, not near-term cash. The $40 million Sanofi payment and the $25 million grant from the California Institute for Regenerative Medicine (announced last month alongside STX-1150's clinical entry) are the harder numbers: cash actually received.

---

## IPO Market Context: 2026 Is Strong, But Gene Editing Has Baggage

The broader 2026 biotech IPO environment is favorable. The source notes the year has already produced two of the largest biotech offerings on record. Fellow cardiometabolic company Kardigan raised $400 million in June, providing a direct comp in both therapeutic focus and timing. The pipeline is warm.

Gene editing specifically is a different story. Metagenomi's nearly $94 million raise in 2024 was the last gene editing IPO — and the sector has not recovered the valuations or investor enthusiasm that characterized 2020–2021. Public [cell therapy](https://synbiointel.com/glossary/cell-therapy) and gene therapy stocks have broadly underperformed. Scribe's epigenetic silencing framing — deliberately distancing from "permanent DNA alteration" — reads partly as a scientific choice and partly as a market positioning exercise to avoid the reputational weight that "gene editing" carries with post-2021 public investors.

Andreessen Horowitz, Avoro Ventures, and OrbiMed are the named venture backers. All three have healthcare-focused funds with experience navigating biotech public markets, which reduces the likelihood of a rushed or poorly structured offering.

---

## What This Means for the Broader Synbio Therapeutics Sector

Scribe's filing is the clearest signal yet that epigenomic editing — the category that includes [Tune Therapeutics](https://synbiointel.com/companies/tune-therapeutics) and [Chroma Medicine](https://synbiointel.com/companies/chroma-medicine) in its competitive set — is ready to face public market scrutiny. A successful Scribe IPO would validate the funding model for non-permanent gene regulation and likely accelerate IPO planning at comparable private companies. A failed or pulled offering would set the category back by at least 12–18 months in terms of public market access.

The cardiometabolic angle is commercially shrewd. PCSK9 is a proven, multi-billion-dollar validated target. The debate is not whether PCSK9 inhibition works — it demonstrably does — but whether epigenetic silencing can deliver comparable or superior LDL reduction with a more convenient dosing profile and an acceptable long-term safety record. That is a tractable question the Phase 1 data can begin to answer.

Investors who missed Kardigan's cardiometabolic IPO window in June now have a second opportunity in the same disease area with a differentiated mechanism. Whether that differentiator justifies the additional clinical-stage risk relative to Kardigan's presumably more advanced position is the central underwriting judgment.

---

## Key Takeaways

- Scribe Therapeutics has filed SEC paperwork to list on Nasdaq under "SCTX," targeting the gene editing IPO window last accessed by Metagenomi in 2024.
- Lead asset STX-1150, an epigenetic PCSK9 silencer, entered Phase 1 last month; no efficacy data is publicly available yet.
- The company has raised $120 million in venture funding and received more than $25 million in CIRM grant funding.
- Pharma collaborations include a Lilly deal worth up to $1.5 billion in milestones (two already hit), a $40 million expanded Sanofi partnership, and a multi-target Biogen ALS collaboration.
- A successful IPO would be the first public market test of epigenetic silencing as a standalone investment thesis and could re-open the gene editing IPO window closed since 2024.
- The 2026 biotech IPO market is broadly favorable; Kardigan's $400 million cardiometabolic raise in June is the most relevant direct comparable.

---

## Frequently Asked Questions

**What is Scribe Therapeutics' lead drug candidate?**
STX-1150, an epigenetic silencing treatment targeting the PCSK9 gene for high cholesterol. It entered Phase 1 clinical trials last month and is designed as a single-dose therapy, distinguishing it from daily statins and quarterly injectable PCSK9 inhibitors.

**How much has Scribe Therapeutics raised before its IPO?**
Scribe has raised $120 million in venture funding, with backers including Andreessen Horowitz, Avoro Ventures, and OrbiMed. It also received more than $25 million in grant funding from the California Institute for Regenerative Medicine.

**What makes Scribe's gene editing approach different from standard CRISPR?**
Scribe uses epigenetic silencing to suppress gene expression without permanently altering the DNA sequence. This avoids the heritable DNA cuts associated with nuclease-based editing and may carry a different regulatory and safety profile than conventional CRISPR-Cas9 approaches.

**Who are Scribe's pharma partners?**
Biogen (ALS, expanded to a second target), Sanofi (natural killer cell cancer therapies and in vivo gene therapies), and Eli Lilly's Prevail Medicines subsidiary (neurological conditions, deal worth up to $1.5 billion in milestones).

**When was the last gene editing company IPO before Scribe?**
Metagenomi, also based in the San Francisco Bay Area, raised nearly $94 million in its IPO in 2024 — making it the most recent gene editing company to price a public offering before Scribe's filing.